<DOC>
	<DOC>NCT00649090</DOC>
	<brief_summary>The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen and to collect all serious adverse events.</brief_summary>
	<brief_title>A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal patients Patients with early breast cancer after adequate locoregional treatment and eventual adjuvant chemotherapy, treated with tamoxifen for 23 years OR treated with tamoxifen for 23 years and consecutive exemestane treatment, provided the total duration of endocrine treatment is less than 5 years Estrogen receptor positive breast cancer patients Patients who remain free from disease following treatment with tamoxifen Patients taking other drugs for the adjuvant treatment of breast cancer Patients taking hormone replacement therapy Donation of blood or blood products for transfusion during the 30 days prior to initiation of treatment with study drug, at any time during the program or 30 days after completion of treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>